文献速递免疫规划慢病防控与筛查

四价人乳头瘤病毒疫苗在男孩中接种与自身免疫性疾病、神经系统疾病及静脉血栓栓塞风险

Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism.
PubMed 文献 · Int J Epidemiol · 2018-01-01

结果显示,qHPV接种男孩中自身免疫性疾病合并组RR=0.96(95%CI:0.71—1.28,n=46例)、神经系统疾病合并组RR=0.67(0.41—1.10,n=16例)、静脉血栓栓塞RR=0.88(0.33—2.35,n=4例),经多重检验校正后52个个体结局均未见超额发生。

要点

  • 10—17岁男孩接种qHPV疫苗后,自身免疫性疾病合并组RR=0.96(95%CI:0.71—1.28,n=46例)。
  • 神经系统疾病合并组RR=0.67(95%CI:0.41—1.10,n=16例),静脉血栓栓塞RR=0.88(95%CI:0.33—2.35,n=4例)。
  • 经多重检验校正后,52个个体结局均未见超额发生。

核心结论

  • qHPV疫苗接种与10—17岁男孩自身免疫性疾病、神经系统疾病或静脉血栓栓塞风险升高不相关。
  • 作者指出虽需进一步大规模流行病学研究,但本研究提供了qHPV接种男孩不增加上述疾病风险的群体层面 reassurance。

研究设计与样本

  • 利用全国登记数据获取qHPV疫苗接种剂量及39种自身免疫性疾病、12种神经系统疾病和静脉血栓栓塞的住院记录。
  • 按qHPV疫苗接种状态估计各结局的发病率比(RR)及95%CI。

主要发现

  • 7384名男孩在10—17岁至少接种一剂qHPV疫苗。
  • 自身免疫性疾病合并组RR=0.96(95%CI:0.71—1.28,qHPV接种男孩n=46例)。
  • 神经系统疾病合并组RR=0.67(95%CI:0.41—1.10,n=16例)。
  • 静脉血栓栓塞RR=0.88(95%CI:0.33—2.35,n=4例)。
  • 经多重检验校正后,52个个体结局均未见超额发生。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需进一步大规模流行病学研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, human papillomavirus (HPV) vaccination of boys has been added to childhood vaccination programmes in several countries but, so far, no systematic population-based assessment with long-term follow-up has been undertaken of the relative incidence of adverse outcomes following HPV vaccination in this group. We investigated if quadrivalent HPV (qHPV) vaccination of 10-17-year-old boys is associated with any unusual risk of autoimmune diseases, neurological diseases or venous thromboembolism. METHODS: We conducted a national cohort study of 568 410 boys born in Denmark 1988-2006 and followed for 4 million person-years during 2006-16, using nationwide registers to obtain individual-level information about received doses of the qHPV vaccine and hospital records for 39 autoimmune diseases, 12 neurological diseases and venous thromboembolism. For each outcome, we estimated incidence rate ratios (RRs) with 95% confidence intervals (CIs) according to qHPV vaccination status. RESULTS: Altogether 7384 boys received at least one dose of the qHPV vaccine at age 10-17 years. Overall, RRs were close to unity for the combined groups of autoimmune diseases (RR = 0.96; 95% CI: 0.71-1.28, n = 46 cases in qHPV-vaccinated boys) and neurological diseases (RR = 0.67; 0.41-1.10, n = 16), as well as for venous thromboembolism (RR = 0.88; 0.33-2.35, n = 4). After taking multiple testing into account, none of the 52 individual outcomes studied appeared to occur in excess among qHPV-vaccinated boys. CONCLUSIONS: Although additional large-scale epidemiological studies are warranted, our findings provide population-based reassurance that qHPV vaccination of 10-17-year-old boys is unlikely to be associated with an elevated risk of autoimmune diseases, neurological diseases or venous thromboembolism.

来源:Int J Epidemiol,查看原文。版权归原作者所有。

引用

  1. Frisch M, Besson A, Clemmensen KKB, et al. Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism. Int J Epidemiol. 2018. PMID: 29425361. doi:10.1093/ije/dyx273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。